Leidos was founded in 1969 and is headquartered in Reston, US
Key People at Leidos
Roger A. Krone
Chairman & Chief Executive Officer
James C. Reagan
Chief Financial Officer
John Fratamico
Chief Technology Officer
Mary Craft
Chief Administrative Officer
Gerry Fasano
Chief of Business Development & Strategy
Michele M. Brown
Chief Ethics & Compliance Officer
Leidos Office Locations
Leidos has an office in Reston
Reston, US (HQ)
11951 Freedom Dr
Leidos Data and Metrics
Leidos Financial Metrics
Leidos's revenue was reported to be $2.6 b in Q1, 2017
USD
Revenue (Q1, 2017) | 2.6 b |
Gross profit (Q1, 2017) | 310 m |
Gross profit margin (Q1, 2017), % | 12% |
Net income (Q1, 2017) | 74 m |
EBIT (Q1, 2017) | 141 m |
Market capitalization (17-Aug-2017) | 8.4 b |
Cash (31-Mar-2017) | 206 m |
Leidos's current market capitalization is $8.4 b.
- Source: SEC Filings
| USD | Y, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Revenue | 5.8 b | 5.1 b | 7 b |
Revenue growth, % | (12%) | 39% | |
Cost of goods sold | 4.1 b | ||
Gross profit | 2.9 b | ||
Gross profit Margin, % | 41% | ||
General and administrative expense | 201 m | ||
Operating expense total | 201 m | ||
EBIT | (214 m) | 320 m | |
EBIT margin, % | (4%) | 5% | |
Interest expense | (53 m) | ||
Interest income | 4 m | ||
Pre tax profit | 355 m | ||
Income tax expense | (112 m) | ||
Net Income | (323 m) | 246 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.3 b | 1.3 b | 1.2 b | 1.3 b | 1.3 q | 1.3 b | 1.3 b | 1.9 b | 2.6 b |
Cost of goods sold | 1.1 b | 1.1 b | 1.1 b | 1.1 b | 1.1 q | 1.2 b | 1.1 b | 1.6 b | 2.3 b |
Gross profit | 187 m | 161 m | 153 m | 144 m | 160 t | 158 m | 147 m | 238 m | 310 m |
Gross profit Margin, % | 14% | 13% | 12% | 11% | 12% | 12% | 11% | 13% | 12% |
General and administrative expense | 87 m | 72 m | 75 m | 51 m | 53 t | 60 m | 57 m | 87 m | 144 m |
Operating expense total | 87 m | 72 m | 75 m | 51 m | 53 t | 60 m | 57 m | 87 m | 144 m |
EBIT | (410 m) | 72 m | 38 m | 64 m | 94 t | 89 m | 75 m | 101 m | 141 m |
EBIT margin, % | (31%) | 6% | 3% | 5% | 7% | 7% | 6% | 5% | 5% |
Interest expense | (20 m) | (18 m) | (14 m) | (14 m) | (14 t) | (11 m) | (13 m) | (28 m) | (38 m) |
Interest income | 1 m | 3 m | 2 m | ||||||
Pre tax profit | (430 m) | 54 m | 23 m | 52 m | 80 t | 78 m | 60 m | 75 m | 108 m |
Income tax expense | (9 m) | (16 m) | (15 m) | (31 t) | (29 m) | (19 m) | 17 m | (34 m) | |
Net Income | (438 m) | 34 m | 41 m | 37 m | 49 t | 49 m | 41 m | 92 m | 74 m |
- Source: SEC Filings
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Cash | 430 m | 443 m | 376 m |
Current Assets | 1.8 b | 1.6 b | 2.4 b |
PP&E | 483 m | 308 m | 259 m |
Goodwill | 1.7 b | 1.2 b | 4.6 b |
Total Assets | 4.2 b | 3.3 b | 9.1 b |
Accounts Payable | 1.4 b | ||
Dividends Payable | 23 m | ||
Current Liabilities | 1 b | 951 m | 2 b |
Additional Paid-in Capital | 1.6 b | 1.4 b | 3.3 b |
Retained Earnings | 25 m | (177 m) | |
Total Equity | 1.6 b | 998 m | 3.1 b |
Financial Leverage | 2.6 x | 3.3 x | 2.9 x |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 358 m | 418 m | 377 m | 365 m | 635 m | 609 m | 670 m | 449 m | 206 m |
Current Assets | 1.7 b | 1.7 b | 1.7 b | 1.7 b | 1.7 b | 1.8 b | 1.8 b | 2.6 b | 2.4 b |
PP&E | 231 m | 238 m | |||||||
Goodwill | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 4.9 b | 4.6 b |
Total Assets | 3.5 b | 3.4 b | 3.3 b | 3.2 b | 3.3 b | 3.4 b | 3.4 b | 9.6 b | 9.1 b |
Accounts Payable | 682 m | 704 m | 745 m | 716 m | 771 m | 707 m | 720 m | 1.5 b | 592 m |
Dividends Payable | 23 m | 21 m | |||||||
Current Liabilities | 991 m | 1 b | 987 m | 996 m | 1 b | 1 b | 990 m | 2 b | 2 b |
Additional Paid-in Capital | 1.4 b | 1.4 b | 1.4 b | 1.3 b | 1.3 b | 1.4 b | 1.4 b | 3.3 b | 3.3 b |
Retained Earnings | (419 m) | (406 m) | (380 m) | (251 m) | (230 m) | (188 m) | (154 m) | ||
Total Equity | 919 m | 954 m | 1.1 b | 1.1 b | 3.1 b | 3.2 b | |||
Financial Leverage | 3.5 x | 3.5 x | 3.1 x | 3 x | 3.1 x | 2.9 x |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | 164 m | (323 m) | 242 m |
Depreciation and Amortization | 81 m | 62 m | 41 m |
Cash From Operating Activities | 13 m | ||
Purchases of PP&E | (53 m) | (29 m) | (27 m) |
Long-term Borrowings | (39 m) | ||
Dividends Paid | (95 m) | (93 m) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (438 m) | 34 m | 41 m | 37 m | 49 t | 49 m | 41 m | 92 m | 74 m |
Accounts Payable | 592 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 78.2 k |
Financial Leverage | 2.9 x |
Leidos Operating Metrics
Leidos's Locations was reported to be 341 in FY, 2016, which is a 44% increase from the previous period
- Source: SEC Filings
Leidos Market Value History
Leidos Revenue Breakdown
Leidos Median Salaries
Source: 158 public H-1B filings from Leidos
Market Position of Leidos
Traffic Overview of Leidos
Leidos Online and Social Media Presence
Leidos News and Updates
June 23, 2016
BRIEF-Immunovaccine awarded subcontract to evaluate depovax for development of malaria vaccine targets
* Awarded a subcontract by leidos to evaluate
immunovaccine's depovax(tm) platform for development of peptide
based malaria vaccine targets
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)